α-2,3-sialyltransferase

EV-3001

Synonyms: β-Galactoside α-2,3-sialyltransferase, CMP-N-Acetylneuraminate:β-D-galactosyl-1,4-N-acetyl-β-D-glucosamine α-2,3-N-acetylneuraminyltransferase
Unit definition (U) (standard enzyme unit): One unit is defined as the formation of 1 μmol Neu5Ac-α-2,3-lactose (3'SL) from 1 mM CMP-Neu5Ac and 1 mM lactose per minute at 37 °C and pH 8.0.

‍

Quantity

€ 290.00 EUR

Excl. VAT + Shipping

Receive a Quote

This product is out of stock.

Product is not available in this quantity.

Product Specs

Technical product information

Description

This recombinant bacterial α-2,3-sialyltransferase (α2,3SiaT) is expressed in E. coli BL21(DE3) and is designed for sialylation of glycoproteins, glycolipids and free glycans including oligosaccharides. It catalyzes the transfer of sialic acid from CMP-Neu5Ac (or other CMP-Neu5Ac analogues) to terminal galactose residues in an α-2,3 linkage. Compared to other known α2,3SiaTs, this enzyme has suppressed hydrolytic activities, resulting in enhanced synthesis efficiency.

Other identifiers

Unit definition (U): formation of 1 µmol 3'SL from 1 mM CMP-Neu5Ac and 1 mM lactose per minute at 37 °C, pH 8.0.

Appearance

Lyophilized powder

Molecular Weight (MW)

48 kDa

Expression host

E. coli BL21(DE3)

Purity

> 90 % (SDS-PAGE)

Solubility

Storage

At -20 °C

Special instructions

For research use only. Not for use in diagnostic procedures.

His-tag

Yes

Reconstitution

Mix 100–1000 µL deionized water per 1 mg lyophilized powder. Exchange buffer if needed.

Toxicity & Safety

Enzymatic activity characterisation

• Donor substrate: CMP-Neu5Ac and CMP-Neu5Ac analogues

• Acceptor substrate: Glycans with terminal galactose

• Reaction conditions: pH 7.0 – 8.0; 20 – 37 °C

• Transferase activity: α-2,3-sialyltransferase• Hydrolytic activity: Undetectable

• Sialidase activity: Undetectable

‍

Availability

Application Examples

• For the sialylation of a wide range of glycans with galactose terminal: G2F, G2, Lewis a, Lewis x, lactose, LNT, LNnT, etc.

• For the sialylation of glycoproteins: Rituximab (in combination with β1,4-GalT), Erythropoietin (EPO) for terminal sialylation, Fc-fusion proteins for enhanced serum half-life

• Glycan arrays for binding studies

‍

Product Datasheet / CoA / MSDS

Technical Product information

Sample CoA

MSDS

MSDS - animal free

Citations